Volume 7 Supplement 1

Proceedings of the 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access

The AIDS malignancy clinical trials consortium (AMC) patient navigator (PN) initiative

  • Maria T Botello-Harbaum1Email author,
  • Kimberly Mosby1,
  • Don Vena1 and
  • David M Aboulafia2, 3
Infectious Agents and Cancer20127(Suppl 1):P24

DOI: 10.1186/1750-9378-7-S1-P24

Published: 19 April 2012


Cancer remains a major health concern in the management of HIV infection in areas of the world with and without access to highly active antiretroviral therapy. In the USA alone, approximately 56,000 people were newly diagnosed with HIV infection in 2006; 53% of these new diagnosis occurred in gay and bisexual men but Black/African American men (45%) ,women (27%) , and Hispanics (17%) were also strongly affected [1]. Recruitment of members of these groups into cancer clinical trials has traditionally been challenging [2]. Among domestic AMC studies, a relatively small percentage of all participants have included women (8%), African-Americans (29%), and Hispanics (21%). Patient Navigation has been identified as an effective strategy to reduce barriers to care as well as to increase access to cancer clinical trials [3]. In an effort to bolster opportunities for HIV-infected minorities, women, and medically underserved populations to become involved in AMC clinical trials, a PN initiative was implemented in seven AMC sites located in Boston, Los Angeles, San Diego, Houston, Columbus, and Honolulu. The main objectives of the PN initiative were to provide greater opportunity for minority groups and women to participate in AMC-sponsored cancer trials and to increase awareness of HIV/AIDS malignancies in the local communities where the PNs worked. From January 2010 to April 2011, PNs implemented multi-strategy activities to increase the enrollment of women and minorities in AMC trials. PNs reported 466 activities in the programmatic areas of recruitment and retention, community outreach and education and awareness. Recruitment and retention refers activities to recruit new participants and increase retention in AMC trials. Community outreach was targeted to the medical community or the general population to increase their awareness of AIDS-related malignancies. Education and awareness were activities to educate the community on HIV-related malignancies in general and AMC-sponsored clinical trials in specific. PNs efforts were concentrated on community outreach (54%, n=251), followed by recruitment and retention (28%, n=129) and education and awareness 18% (n=86).


AMC-PNs conducted activities that raised awareness in their local communities of AIDS-related malignancies, developed partnerships with local health community organizations and identified areas where further communication was needed. PNs took the lead in developing a PN brochure and in the design of several tailored recruitment strategies. The PN program is making important inroads into behavioral interventions to increase participation of minorities and underserved populations in AMC trials.



The AMC PNs Participating Principal Investigators and Patient Navigators and a supplemental grant from NIH/NCI U01CA121947.

Authors’ Affiliations

AMC Data and Coordinating Center, The EMMES Corporation
Division of Hematology-Oncology, Virginia Mason Medical Center
The Division of Hematology, University of Washington


  1. Hall HI, Song R, Rhodes P, Prejean J, An O, Lee LM: Estimation of HIV Incidence in the United States. JAMA. 2008, 300: 520-529. 10.1001/jama.300.5.520.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Colon-Otero G, Smallridge RC, Solberg LA, Keith TD, Woodward TA, Willis FB, Dunn AN: Disparities in participation in cancer clinical trials in the United States: a symptom of a healthcare system in crisis. Cancer. 2008, 112: 447-454. 10.1002/cncr.23201.View ArticlePubMedGoogle Scholar
  3. Steinberg ML, Fremont A, Khan DC, Huang D, Knapp H, Karaman D, Forge N, Andre K, Chaiken LM, Streeter OE: Lay patient navigator program implementation for equal access to cancer care and clinical trials. Cancer. 2006, 107: 2669-2677. 10.1002/cncr.22319.View ArticlePubMedGoogle Scholar


© Botello-Harbaum et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.